Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries G1 Therapeutics Inc (NQ: GTHX ) 3.930 +0.180 (+4.80%) Streaming Delayed Price Updated: 12:24 PM EDT, Jul 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,019,606 Open 3.710 Bid (Size) 3.920 (2) Ask (Size) 3.930 (2) Prev. Close 3.750 Today's Range 3.710 - 4.255 52wk Range 1.080 - 6.140 Shares Outstanding 42,705,532 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 July 25, 2024 From G1 Therapeutics Via GlobeNewswire G1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025 July 15, 2024 While there’s no denying that G1 Therapeutics stock is highly speculative, investors should still check under the hood. Via InvestorPlace Performance YTD +26.37% +26.37% 1 Month +59.11% +59.11% 3 Month +5.65% +5.65% 6 Month -13.44% -13.44% 1 Year +63.75% +63.75% More News Read More Biotech Bombshell: G1 Therapeutics Stock Is Too Much of a Gamble July 10, 2024 Via InvestorPlace Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday June 25, 2024 Via Benzinga Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears June 24, 2024 Via InvestorPlace Exposures Product Safety Analyst Ratings For G1 Therapeutics June 13, 2024 Via Benzinga Evaluating G1 Therapeutics: Insights From 5 Financial Analysts May 01, 2024 Via Benzinga Breaking Down G1 Therapeutics: 5 Analysts Share Their Views April 12, 2024 Via Benzinga Ginkgo Bioworks Layoffs 2024: What to Know About the Latest DNA Job Cuts June 24, 2024 Via InvestorPlace Topics Workforce Exposures Layoff Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge June 24, 2024 Via Benzinga Why Is Cancer-Focused G1 Therapeutics Stock Trading Lower On Monday? June 24, 2024 Via Benzinga Why Is G1 Therapeutics (GTHX) Stock Down 56% Today? June 24, 2024 Via InvestorPlace Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday June 24, 2024 Via InvestorPlace G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC) June 24, 2024 From G1 Therapeutics Via GlobeNewswire 10 Health Care Stocks With Whale Alerts In Today's Session June 11, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session May 28, 2024 Via Benzinga Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC) May 28, 2024 From G1 Therapeutics Via GlobeNewswire Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session May 28, 2024 Via Benzinga G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting May 23, 2024 From G1 Therapeutics Via GlobeNewswire G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses May 22, 2024 From G1 Therapeutics Via GlobeNewswire What's Going On With G1 Therapeutics Stock? May 09, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session May 09, 2024 Via Benzinga GTHX Stock Earnings: G1 Therapeutics Beats EPS, Misses Revenue for Q1 2024 May 01, 2024 Via InvestorPlace G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights May 01, 2024 From G1 Therapeutics Via GlobeNewswire G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib May 01, 2024 From G1 Therapeutics Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
